Summary
89.69 0.05(0.06%)09/27/2024
Axsome Therapeutics Inc (AXSM)
Axsome Therapeutics Inc (AXSM)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.19 | -6.41 | 0.81 | 11.85 | 13.19 | 24.10 | 306.02 | 926.20 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 89.69 | |
| Open | 90.08 | |
| High | 91.30 | |
| Low | 89.04 | |
| Volume | 187,923 | |
| Change | 0.17 | |
| Change % | 0.19 | |
| Avg Volume (20 Days) | 274,299 | |
| Volume/Avg Volume (20 Days) Ratio | 0.69 | |
| 52 Week Range | 55.03 - 98.40 | |
| Price vs 52 Week High | -8.85% | |
| Price vs 52 Week Low | 62.98% | |
| Range | -0.43 | |
| Gap Up/Down | -0.41 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,303 | |
| EBIDTA | -41,298,216 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 86.00 | |
| Book Value | 1.1330 | |
| Earnings Per Share | -3.3480 | |
| EPS Estimate Current Quarter | -0.9500 | |
| EPS Estimate Next Quarter | -1.0300 | |
| EPS Estimate Current Year | -3.5900 | |
| EPS Estimate Next Year | -3.9100 | |
| Diluted EPS (TTM) | -3.3480 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.4676 | |
| Return on equity (TTM) | -1.4113 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 29.2496 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 37,691,700 | |
| Shares Float | 29,630,225 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 21.42 | |
| Institutions (%) | 52.30 | |
09/05 12:35 EST - zacks.com
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025.
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025.
09/04 12:35 EST - zacks.com
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
09/04 07:00 EST - globenewswire.com
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Company's New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Company's New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.
08/21 07:00 EST - globenewswire.com
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has reached agreement with Sandoz Inc. (Sandoz) to dismiss the patent litigation related to Axsome's product Sunosi® (solriamfetol). The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. Sandoz withdrew its ANDA for a generic equivalent of Sunosi, and, as a result, the litigation has been dismissed without prejudice.
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has reached agreement with Sandoz Inc. (Sandoz) to dismiss the patent litigation related to Axsome's product Sunosi® (solriamfetol). The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. Sandoz withdrew its ANDA for a generic equivalent of Sunosi, and, as a result, the litigation has been dismissed without prejudice.
08/15 12:06 EST - zacks.com
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity.
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity.
08/10 21:00 EST - globenewswire.com
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was filed against Axsome on May 13, 2022 with a Class Period from December 30, 2019 to April 22, 2022. Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company.
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc. (NASDAQ: AXSM) on behalf of long-term stockholders following a class action complaint that was filed against Axsome on May 13, 2022 with a Class Period from December 30, 2019 to April 22, 2022. Our investigation concerns whether the board of directors of Axsome have breached their fiduciary duties to the company.
08/06 15:45 EST - seekingalpha.com
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company's SG&A and R&D expenses significantly increased, leading to wider net losses despite revenue growth. Auvelity faces stiff competition in the depression market, with uncertain positioning and high marketing expenses.
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company's SG&A and R&D expenses significantly increased, leading to wider net losses despite revenue growth. Auvelity faces stiff competition in the depression market, with uncertain positioning and high marketing expenses.
08/05 12:30 EST - zacks.com
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
Axsome (AXSM) Q2 Loss Widens Y/Y, Revenues Beat Estimates
Axsome's (AXSM) bottom line declines year over year in the second quarter. Strong sales of Auvelity drive revenues.
08/05 12:15 EST - fool.com
Why Axsome Therapeutics Stock Is Sinking Today
Axsome's Q2 revenue beat estimates, but the company posted a wider net loss than expected. The primary culprit behind the disappointing bottom line were noncash charges of $26 million.
Why Axsome Therapeutics Stock Is Sinking Today
Axsome's Q2 revenue beat estimates, but the company posted a wider net loss than expected. The primary culprit behind the disappointing bottom line were noncash charges of $26 million.
08/05 11:20 EST - seekingalpha.com
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Conference Call Participants Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald Joon Lee - Truist Securities Raghuram Selvaraju - H.C. Wainwright Jason Gerberry - Bank of America Ami Fadia - Needham & Company Yatin Suneja - Guggenheim Partners David Amsellem - Piper Sandler Joel Beatty - Baird Joseph Thome - TD Cowen David Hoang - Citigroup Graig Suvannavejh - Mizuho Securities Ashwani Verma - UBS Myles Minter - William Blair Matt Kaplan - Ladenburg Thalmann Operator Hello, and welcome to the Axsome Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.
Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Conference Call Participants Vikram Purohit - Morgan Stanley Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Charles Duncan - Cantor Fitzgerald Joon Lee - Truist Securities Raghuram Selvaraju - H.C. Wainwright Jason Gerberry - Bank of America Ami Fadia - Needham & Company Yatin Suneja - Guggenheim Partners David Amsellem - Piper Sandler Joel Beatty - Baird Joseph Thome - TD Cowen David Hoang - Citigroup Graig Suvannavejh - Mizuho Securities Ashwani Verma - UBS Myles Minter - William Blair Matt Kaplan - Ladenburg Thalmann Operator Hello, and welcome to the Axsome Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.
08/05 11:01 EST - zacks.com
Does Axsome (AXSM) Have the Potential to Rally 48.44% as Wall Street Analysts Expect?
The mean of analysts' price targets for Axsome (AXSM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Axsome (AXSM) Have the Potential to Rally 48.44% as Wall Street Analysts Expect?
The mean of analysts' price targets for Axsome (AXSM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
08/05 09:11 EST - zacks.com
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1 per share a year ago.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1 per share a year ago.
08/05 07:00 EST - globenewswire.com
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in migraine resubmitted Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024 Topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024; target enrollment reached Topline results of FOCUS Phase 3 trial of solriamfetol in ADHD anticipated 2H 2024 SUSTAIN Phase 3 trial of solriamfetol in shift work disorder initiated NDA submission for AXS-14 in fibromyalgia expected 3Q 2024 NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced financial results for the second quarter of 2024. “We delivered another robust quarter driven by focused commercial execution and continued pipeline advancement,” said Herriot Tabuteau, MD, CEO of Axsome Therapeutics.
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing 16% year-over-year growth NDA for AXS-07 in migraine resubmitted Topline results of ADVANCE-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024 Topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024; target enrollment reached Topline results of FOCUS Phase 3 trial of solriamfetol in ADHD anticipated 2H 2024 SUSTAIN Phase 3 trial of solriamfetol in shift work disorder initiated NDA submission for AXS-14 in fibromyalgia expected 3Q 2024 NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced financial results for the second quarter of 2024. “We delivered another robust quarter driven by focused commercial execution and continued pipeline advancement,” said Herriot Tabuteau, MD, CEO of Axsome Therapeutics.
07/29 11:06 EST - zacks.com
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/29 10:45 EST - zacks.com
5 Biotech Stocks to Bet On Bright Industry Prospects
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.
5 Biotech Stocks to Bet On Bright Industry Prospects
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.
07/23 14:57 EST - investorplace.com
7 Biotech Stocks to Keep on Your Clinical Radar
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.
7 Biotech Stocks to Keep on Your Clinical Radar
Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.
07/23 04:06 EST - seekingalpha.com
Axsome Therapeutics: Lots Of Moving Parts
Today, we circle back to mid-cap biopharma Axsome Therapeutics, which has multiple potential catalysts on the horizon. The company has two approved products on the market and the potential to have six FDA approved drugs by the end of 2025. Analyst firms are largely positive on the shares, and explosive sales growth is projected over the next few years.
Axsome Therapeutics: Lots Of Moving Parts
Today, we circle back to mid-cap biopharma Axsome Therapeutics, which has multiple potential catalysts on the horizon. The company has two approved products on the market and the potential to have six FDA approved drugs by the end of 2025. Analyst firms are largely positive on the shares, and explosive sales growth is projected over the next few years.
07/18 10:56 EST - zacks.com
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should Know
The mean of analysts' price targets for Axsome (AXSM) points to a 49.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should Know
The mean of analysts' price targets for Axsome (AXSM) points to a 49.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
07/15 07:15 EST - fool.com
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Vertex Pharmaceuticals and Axsome Therapeutics are moving toward key regulatory approvals. Thanks to solid tailwinds, both biotechs should handsomely reward investors over the long run.
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Vertex Pharmaceuticals and Axsome Therapeutics are moving toward key regulatory approvals. Thanks to solid tailwinds, both biotechs should handsomely reward investors over the long run.
07/05 14:14 EST - investorplace.com
The 3 Best Biotech Stocks to Buy in July 2024
Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.
The 3 Best Biotech Stocks to Buy in July 2024
Investing in biotech can be pretty unpredictable. Biotech stocks are highly volatile, and picking carefully can be the difference between losing all your capital and making unimaginable profits.